CELERA (NASDAQ:CRA)
6.21
0.08 (1.27%)
| CELERA (NASDAQ:CRA) Delayed : | |||||
|---|---|---|---|---|---|
| Previous Close | $6.29 | 52 Week High | $11.71 | ||
| Open | $6.29 | 52 Week Low | $5.03 | ||
| Day High | $6.34 | P/E | N/A | ||
| Day Low | $6.20 | EPS | $-1.49 | ||
| Volume | 189,962 | ||||
| More CRA Info: Chart SEC Filings Profile Historical Options | |||||
Celera Group Summary
Celera Group, a molecular diagnostics business, engages in the identification and validation of diagnostic markers using proprietary genomics and proteomics discovery platforms. The company, through its strategic alliance with Abbott Laboratories, discovers, develops, and commercializes in vitro diagnostic products for disease detection, prediction of disease predisposition, disease progression monitoring, and therapy ...more
Executives
Tony White - Chairman, CEO, President
Links
What is this?Friends, Peers and Foes
| Ticker | # Stories | Ticker | # Stories |
|---|---|---|---|
| ABT | 3 | ISRG | 3 |
| VMW | 3 | EBAY | 3 |
| AATI | 2 | SNDK | 2 |
| CRE5 | 2 | SPF | 2 |
| AFFX | 2 | SNDK | 2 |
| TBI | 2 | FREE | 2 |
Entities who have mentioned CRA
- JPMorgan | View Related Stories »
- Thomas Weisel Partners Group | View Related Stories »
- Dividend | View Related Stories »
- Warren Buffett | View Related Stories »
- Barack Obama | View Related Stories »
- Piper Jaffray | View Related Stories »
- Citi | View Related Stories »
- Jefferies & Co | View Related Stories »
- UBS | View Related Stories »
- Barclays | View Related Stories »
- Robert W Baird | View Related Stories »
- StreetInsider.com Morning Movers | View Related Stories »
- American Technology Research | View Related Stories »
- Trading Radar | View Related Stories »
- Wedbush Morgan | View Related Stories »
- William Blair | View Related Stories »
- Bankruptcy | View Related Stories »
- Needham & Co | View Related Stories »
- Susquehanna International Group of Companies | View Related Stories »
- Morgan Stanley | View Related Stories »
- Notable Analyst Rating Changes | View Related Stories »
- Cowen & Co | View Related Stories »
- Jim Cramer | View Related Stories »
- Unusual 11 Mid-Day Movers | View Related Stories »
- Initial Jobless Claims | View Related Stories »
View All Major News StreetInsider.com Major News for CRA
- Celera (CRA) Posts Q3 Loss of $0.09
- Celera (CRA) Reports a Q2 Loss; Guides Below for FY Revenues
- Celera (CRA) Cuts Guidance, Workforce
View All ReportsStreetInsider.com Reports on CRA
- Celera (CRA) Posts Q3 Loss of $0.09
- Trading Radar for 10/28: First Solar (FSLR), ConocoPhillips (COP), WellPoint (WLP), Goodyear (GT), Int. Paper (IP) Report
- Celera (CRA) and Medco (MHS) Enter Research Collaboration to Evaluate Effect of KIF6 Testing on Compliance with Statin Therapy in Patients with Cardiovascular Disease
- Celera (CRA) Reports a Q2 Loss; Guides Below for FY Revenues
- Trading Radar for 8/6: NVIDIA (NVDA), Comcast (CMCSA), CBS (CBS), Blackstone (BX), Nasdaq (NDAQ), IMAX (IMAX), Diana Shipping (DSX), Wendy's (WEN), Canadian Solar (CSIQ), Crocs (CROX) Report
View All Press ReleasesCompany Press Releases on CRA
- Trading Outlook for Vermillion Inc. Issued by StockPreacher.com
- Crescent Gold Limited: Quarterly Report 30 September 2009
- Celera Licenses Lung Cancer Intellectual Property from Medical Therapies
- Berkeley HeartLab Enters into Agreements with Proven Diagnostics and Geisinger Medical Center to Provide Testing for Cardiovascular Disease
- Celera Corporation Reports Third Quarter 2009 Results
StreetInsider Reports on CRA by Category
View All BlogsBlogs on CRA
- Analyst upgrades, downgrades and initiations: ADBE, HAL, GCI, GT, IMAX, URBN ...
- Biotech: Q3 Market Update
- The week in preview: Is the rally over?
- VC Financings Boost Interest in Biotech
- Biotech Opportunities: Look for Decent Pipeline, Big Pharma Partnerships
Comments on CRA
No comments are currently available.
